Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5018030 | 1.00 | ALDH1A1 (0.34) | ALDH1A1CYP3A4ALOX15TSHRTDP1 | |
| SCHEMBL3772769 | 0.88 | ALDH1A1 (0.36) | ALDH1A1CYP3A4ALOX15TSHRTDP1 | |
| SCHEMBL5016554 | 0.88 | ALDH1A1 (0.36) | ALDH1A1CYP3A4ALOX15TSHRTDP1 | |
| SCHEMBL1268514 | 0.87 | GAA (0.43) | ALDH1A1CYP3A4ALOX15TSHRTDP1 | |
| SCHEMBL1268677 | 0.85 | MGAM (0.41) | ALDH1A1CYP3A4ALOX15TSHRTDP1 | |
| SCHEMBL27617039 | 0.81 | MGAM (0.38) | ALDH1A1CYP3A4ALOX15TSHRTDP1 | |
| SCHEMBL5023412 | 0.78 | RRM1 (0.36) | ALDH1A1CYP3A4ALOX15TSHRTDP1 | |
| SCHEMBL5023413 | 0.78 | RRM1 (0.36) | ALDH1A1CYP3A4ALOX15TSHRTDP1 | |
| SCHEMBL28479927 | 0.78 | MGAM (0.38) | ALDH1A1CYP3A4ALOX15TSHRTDP1 | |
| SCHEMBL28479929 | 0.78 | MGAM (0.38) | ALDH1A1CYP3A4ALOX15TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312466-A1 | Synthesis and intermediates | OHRLEIN REINHOLD | 2008-12-18 | — | — | US | claimed |
| EP-1404639-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF STATIN DERIVATIVES ESPECIALLY 7-AMINO 3,5-DIHYDROXY HEPTANOIC ACID DERIVATIVES, AND INTERMEDIATES THEREOF | Ciba SC Holding AG (CH) | 2004-04-07 | — | — | EP | claimed |
| WO-2003004450-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF STATIN DERIVATIVES ESPECIALLY 7-AMINO 3,5-DIHYDROXY HEPTANOIC ACID DERIVATIVES, AND INTERMEDIATES THEREOF | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2003-01-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312466-A1 | Synthesis and intermediates | HMGCR, SREBF1, COASY | ALDH1A1 1326/4885CYP3A4 87/4885ALOX15 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.